At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
ALN-CC5 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Single-ascending and Multiple-ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-CC5 in Healthy Adult Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria
In Brief
A Phase 2 clinical trial evaluating ALN-CC5 and Sterile Normal Saline (0.9% NaCl) for Paroxysmal Nocturnal Hemoglobinuria (PNH). Completed, enrolled 62 participants across 4 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-CC5 in healthy adult volunteers and subjects with PNH
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSpain, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedFeb 2015
Primary CompletionApr 2016
Study CompletionAug 2017
TodayJul 2026
First PostedFeb 2, 2015
Enrollment StartJan 1, 2015
Primary CompletionApr 1, 2016
Study CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.4 years ago
Interventions
ALN-CC5drug
Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
Sterile Normal Saline (0.9% NaCl)drug
calculated volume to match active comparator